CytoSorbents Corporation — FY2015 Form 10-K
Reporting period: Fiscal year ended December 31, 2015. This annual filing also provides unaudited quarterly results, including Q4 2015. CytoSorbents develops and commercializes polymer-based blood-purification devices. Its lead product, CytoSorb, had EU CE Mark approval and was sold directly or through partners in 32 countries; it was not FDA-approved for sale in the United States.
Financial performance and liquidity
| Metric | FY2015 | FY2014 |
|---|---|---|
| Total revenue | $4.792 million | $4.123 million |
| Product sales | $4.044 million | $3.135 million |
| Grant income | $0.736 million | $0.978 million |
| Gross profit | $2.579 million | $1.989 million |
| Operating expenses | $11.883 million | $8.882 million |
| Operating loss | $(9.304) million | $(6.893) million |
| Net loss | $(8.132) million | $(9.322) million |
| Net loss per share | $(0.33) | $(1.29) |
| Cash used in operations | $(9.009) million | $(6.661) million |
Q4 2015: Revenue was $1.761 million, gross profit was $0.957 million, operating loss was $2.214 million, and net loss available to common shareholders was $2.002 million.
At year-end, cash and cash equivalents were $5.317 million, short-term investments were $2.192 million, current assets were $9.860 million, current liabilities were $3.044 million, and working capital was $6.817 million. Total assets were $11.254 million and stockholders’ equity was $8.211 million. The balance sheet reported no borrowings; current liabilities included a $1.636 million warrant liability. Management reported approximately $10.3 million of cash burn for the year.
Product gross margin was approximately 62%, versus 63% in 2014. The filing does not provide a clear annual cash-flow margin measure. The company reported an accumulated deficit of $132.526 million. Auditors highlighted substantial doubt about the company’s ability to continue as a going concern.
Material changes versus FY2014
- Total revenue rose 16%; product sales rose 29%, reflecting higher direct and distributor sales. Management estimated the weaker euro reduced 2015 product sales by approximately $637,000.
- Grant income declined approximately $242,000 as several significant grants concluded.
- Operating expenses increased 34%. R&D rose 59% to $3.871 million, largely due to clinical-study costs; selling, general and administrative expense rose 25% to $6.923 million.
- Operating loss widened to $9.304 million from $6.893 million. Net loss narrowed, primarily reflecting a $1.345 million non-cash gain from remeasurement of warrant liability in 2015 versus a $2.118 million non-cash loss in 2014. FY2014 common-shareholder loss also included $9.267 million of preferred-stock dividends.
- Cash increased from $3.605 million to $5.317 million, supported by financing. The company raised approximately $9.409 million net in a January 2015 public offering and received proceeds from warrant and option exercises; fourth-quarter ATM sales generated approximately $225,000 net.
Outlook, commentary, and key risks
- Management said available cash was expected to fund operations through 2016, but additional financing would be required for ongoing operations and clinical trials. A $100 million shelf registration and an ATM facility of up to $25 million provide potential equity capacity, but further issuance could dilute shareholders.
- CytoSorb commercial growth and wider adoption depend on physician uptake, repeat orders, country registration, reimbursement, manufacturing scale-up, and clinical evidence. Reimbursement was established in Germany and Austria; additional reimbursement was not assured.
- Clinical evidence remains limited. The European sepsis trial established safety and cytokine reduction, while reported mortality benefits came from small post-hoc subgroups and require confirmation in larger prospective trials. U.S. cardiac-surgery study REFRESH I was approximately 35% enrolled as of March 4, 2016, with completion expected mid-2016; future trial timing and results were uncertain.
- Management cited more than 50 investigator-initiated studies planned, enrolling, or completed, with 17 enrolling and four completed. Other pipeline products—including HemoDefend, ContrastSorb, DrugSorb, and BetaSorb—were development-stage and lacked regulatory approval.
- Principal risks include recurring losses and going-concern uncertainty; need for capital; failure to obtain FDA or other regulatory approvals; uncertain efficacy and market acceptance; reimbursement and distributor execution; foreign-exchange exposure; manufacturing and scale-up constraints; patent expirations and potential intellectual-property disputes; and product-liability exposure.
- Unusual or material items include the fair-value change in warrant liability affecting reported earnings, foreign-currency transaction losses of $507,000, and royalties recorded on sales under existing agreements. No legal proceedings were pending at filing; the company disclosed no material off-balance-sheet arrangements.
Most important facts for investors to verify
- Whether cash, short-term investments, subsequent New Jersey tax-credit proceeds, and available financing are sufficient for the stated operating and clinical plans, and the resulting dilution risk.
- Underlying product-sales growth and repeat purchasing by geography and channel, including the effect of currency movements and distributor concentration.
- Whether upcoming clinical studies validate efficacy beyond cytokine removal, particularly the small post-hoc sepsis findings and REFRESH I results.
- Current reimbursement, registration, and commercialization status in key markets, plus progress toward U.S. regulatory authorization.
- Manufacturing capacity, product gross margins, and the impact of royalty obligations and near-term patent expirations on economics and competitive protection.